89371-89-1

Upstream product

• 89384-29-2 benzyl (4S)-3-(benzyloxycarbonyl)-2-oxoimidazolidine-4-carboxylate 
• 74-88-4 methyl iodide 
• 59760-01-9 (S)-2-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 
• 100-51-6 benzyl alcohol 
• 2304-96-3 N-benzyloxycarbonyl-L-asparagine 

Downstream Products

• 89371-35-7 benzyl (4S)-1-methyl-2-oxo-imidazolidine-4-carboxylate 
• 89371-40-4 benzyl (4S)-1-methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-n-nonyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylate 

Relevant academic research and scientific papers

GRANZYME B INHIBITOR FORMULATIONS AND METHODS FOR THE TREATMENT OF BURNS

Formulations for treating burns and burn wound healing comprising a Granzyme B inhibitor and a pharmaceutically acceptable carrier, and methods for treating burns and for burn wound healing using the formulations.

CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS

Cyclic urea compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Studies on Angiotensin Converting Enzyme Inhibitors. 4. Synthesis and Angiotensin Converting Enzyme Inhibitory Activities of 3-Acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic Acid Derivatives

(4S)-1-Alkyl-3-acyl>-2-oxoimidazolidine-4-carboxylic acid derivatives (3) were prepared by two methods.Their angiotensin converting enzyme (ACE) inhibitory activities and antihypertensive effects were evaluated, and the structure-activity relationships were discussed.The dicarboxylic acids 3a-n possessing S,S,S configuration showed potent in vitro ACE inhibitory activities with IC 50 values of 1.1x10-8-1.5x10-9 M.The most potent compound in this series, monoester 3p, had an ID 50 value of 0.24 mg/kg, po for inhibition of angiotensin I induced pressor response in normotensive rats and produced a dose-dependent decrease in systolic blood pressure of spontaneously hypertensive rats (SHRs) at doses of 1-10 mg/kg, po.

ANTIHYPERTENSIVE 2-OXO-IMIDAZOLIDINE DERIVATIVES

Novel 2-oxo-imidazolidine derivative of the formula: STR1 wherein R 1 is lower alkyl or phenyl-lower alkyl, R 2 is lower alkyl, R. sup.3 is alkyl of one to 12 carbon atoms or phenyl-lower alkyl and R 4 is hydrogen or lower alkyl, and a pharmaceutically acceptable salts thereof are disclsoed. Said compounds (I) and salts thereof are useful as hypotensive agents.